• Explore /
  • Poster
  • / Phase I/II trial of IMMU-132 (isactuzumab govitecan), an anti-Trop-2-SN-38 antibody drug conjugate (ADC): Results in patients with metastatic gastrointestinal (GI) cancers.

Phase I/II trial of IMMU-132 (isactuzumab govitecan), an anti-Trop-2-SN-38 antibody drug conjugate (ADC): Results in patients with metastatic gastrointestinal (GI) cancers.

Abstract Poster

Authors

null

Alexander Starodub

Indiana University Health, Goshen Center for Cancer Care, Goshen, IN

Alexander Starodub , Allyson J. Ocean , Wells A. Messersmith , Vincent J. Picozzi , Michael J. Guarino , Sajeve Samuel Thomas , Aditya Bardia , Manish A. Shah , Serengulam V. Govindan , Pius P Maliakal , William A. Wegener , Steven A. Hamburger , Robert M. Sharkey , David M. Goldenberg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01631552

Citation

J Clin Oncol 33, 2015 (suppl 3; abstr 703)

DOI

10.1200/jco.2015.33.3_suppl.703

Abstract #

703

Poster Bd #

D45

Abstract Disclosures

Similar Posters

First Author: Alexander Starodub

First Author: Jean-Luc Van Laethem

First Author: Rachel Occhiogrosso Abelman

First Author: Rohit K. Jain